PROCEPT BioRobotics (PRCT)
(Delayed Data from NSDQ)
$57.38 USD
-4.62 (-7.45%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $57.45 +0.07 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PRCT 57.38 -4.62(-7.45%)
Will PRCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRCT
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
PRCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
Other News for PRCT
Strong Buy Rating for PROCEPT BioRobotics Amidst Surging Q2 Performance and Market Adoption
PROCEPT BioRobotics Corp (PRCT) Q2 2024 Earnings Call Transcript Highlights: Record Revenue ...
PROCEPT BioRobotics (PRCT) Receives a Buy from Truist Financial
Strong Growth and Robust Performance Justify Buy Rating for PROCEPT BioRobotics
Piper Sandler Issues a Buy Rating on PROCEPT BioRobotics (PRCT)